 |
|
|
|
|
|
|
|
|
|
|
 |
|
|||||||||
 |
 |
 |
 |
 |
 |
 |
 |
|
||
 |
 |
 |
|
|||||||
 |
|
|||||||||
 |
|
|||||||||
Alert Number 174
Date: July 20, 2024
What makes the new-kid-on-the-block HuMax-CD20 different from the present favorite Rituxan?
I have been pondering this question as I have watched my old friend “Harvey” responding better than I could have hoped to his latest round of therapy with HuMax-CD20, after developing serious hypersensitivity reactions to Rituxan. Compared to Rituxan, HuMax-CD20 is a new upstart. Will this David have any success in taking on the established Goliath of Rituxan? In our latest article A Smarter Monoclonal on Trial I review some of the differences between the two drugs, what makes them tick, why they seem to behave so differently in CLL patients.
We also discuss the full details of the just announced multi-center, Phase-3 clinical trial of Humax-CD20. This trial will recruit 100 CLL patients across the USA and Europe, patients who have relapsed after using fludarabine and Campath. A word to the wise: I think this trial is going to be over-subscribed pretty quickly, so if you are interested you should check it out right away. Not all the centers are recruiting yet, but they should start doing so in the next little while. If you are interested in this trial, you should get your ducks in a row and perhaps have your name on their list of patients looking to enroll.
Be well,
Chaya
_____
NOTICE: This page from the Topics Alert archive was originally emailed to subscribers of Topics Alert, a free service of CLL Topics Inc. If you are not a subscriber and you wish to receive email Alerts, please register at the Topics Alert subscription page. The content of this page is intended for information only and it is NOT meant to be medical advice. Please be sure to consult and follow the advice of your doctors on all medical matters.
———
Disclaimer: The content of this website is intended for information only and is NOT meant to be medical advice. Please be sure to consult and follow the advice of your doctors on all medical matters.
Copyright Notice:
Copyright © 2024-2007 CLL Topics, Inc. All Rights Reserved.
All materials contained on this site are protected by United States copyright law and may not be reproduced, distributed, transmitted, displayed, published or broadcast without the prior written permission of CLL Topics, Inc. You may not alter or remove any trademark, copyright or other notice from copies of the content.
However, you may download and print material from CLLTopics.org exclusively for your personal, noncommercial use.
———
